Zobrazeno 1 - 10
of 81
pro vyhledávání: '"O Atia"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
O Atia, Z Shavit-Brunschwig, A Quteineh, R Lev-Tzion, R Stein, E Broide, D Urlep, J Hyams, M Aloi, D S Shouval, A Assa, S Hussey, J Markowitz, A Yerushalmy, E Miele, R K Russell, D Turner
Publikováno v:
Journal of Crohn's and Colitis. 17:i904-i905
Background We previously reported the effectiveness of vedolizumab (VDZ) to induce remission in children with CD and UC enrolled in the prospective,multicenter VEDOKIDS study.In this extended analysis,we aimed to explore the effectiveness and safety
Autor:
R Lujan, O Atia, G Focht, S Greenfeld, R Kariv, Y Loewenberg Weisband, N Lederman, E Matz, I Dotan, D Turner
Publikováno v:
Journal of Crohn's and Colitis. 17:i975-i976
Background There is uncertainty about the ability to predict disease course in UC, often since prediction studies are small and include selected population. We aimed to use a large nationwide cohort to explore predictors of disease course in UC. Meth
Autor:
G Focht, R Lujan, O Atia, S Greenfeld, R Kariv, Y Loewenberg Weisband, N Lederman, E Matz, I Dotan, D Turner
Publikováno v:
Journal of Crohn's and Colitis. 17:i17-i18
Background Studies have reported conflicting findings regarding the effect of timing of biologics initiation on disease course, often affected by selection and referral biases. In this nationwide cohort study we aimed to explore whether early initiat
Autor:
O Atia, I Goren, T Sharar Fischler, Y Loewenberg Weisband, S Greenfeld, R Kariv, N Ledderman, E Matz, R Magen Rimon, I Dotan, D Turner, H Yanai
Publikováno v:
Journal of Crohn's and Colitis. 17:i596-i596
Background 5-aminosalicylates (5-ASA) are widely used in Crohn's disease (CD) despite guidelines advising otherwise. In this nationwide study, we aimed to assess the outcomes of first-line 5-ASA-maintenance therapy (5-ASA-MT) compared with no-mainten
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Crohn's and Colitis. 16:i584-i585
Background Identifying prognostic factors of therapeutic failure, may facilitate balancing the risks and benefits of biologic treatment. In this population-based study, we aimed to explore predictors of therapeutic failure of biologics in Ulcerative
Autor:
Dan Turner, E Matz, N Ledderman, O Atia, Iris Dotan, Ron Shaoul, Y Loewenberg Weisband, C Friss, Shmuel Odes, R Magen Rimon, C Gabay, Revital Kariv, S Greenfeld
Publikováno v:
Journal of Crohn's and Colitis. 15:S081-S082
Background Therapy in IBD is recommended in order to treat or prevent complications. In this nationwide study we aimed to assess the incidence of patients with IBD who were not receiving maintenance treatment after diagnosis and the duration of non-t
Autor:
O Atia, D Yogev, F Chagit, F Gili, E Orlanski-Meyer, R Magen Rimon, L Natan, G Shira, R Kariv, L W Yisca, H Gabay, D Nevo, E Matz, Y Gorelik, Y Chowers, D Iris, D Turner
Publikováno v:
Journal of Crohn's and Colitis. 15:S082-S083
Background Real-world studies demonstrate that ~33% of CD patients fail to respond to induction therapy with biologics. In this nationwide study we aimed to evaluate trends in biologics utilization and sustainability in CD during the last 15 years. M
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.